secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2026-08-04T10:47:58+00:00
Accession:  0001104659-26-090045
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q2 2026: GAAP loss $0.54 on $16.6B sales; raises FY2026 guidance
----------------------------------------------------------------------

- Total worldwide sales $16.6B, up 5% (4% ex-FX); KEYTRUDA/KEYTRUDA QLEX sales $8.4B (+5%).
- GAAP loss per share $0.54; non-GAAP loss per share $0.13; both include $2.31/share charge for Terns acquisition.
- Full-year 2026 guidance: sales range raised to $66.3B-$67.3B; non-GAAP EPS $2.66-$2.76 (includes $2.43/share Terns charge).
- FDA approved LIPFENDRA (enlicitide), first once-daily oral PCSK9 inhibitor for hypercholesterolemia.
- Completed acquisition of Terns for $6.8B; added MK-4208 (BCR::ABL1 inhibitor) to pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/0001104659-26-090045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-090045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer